Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference
Sept. 1, 2022
Akebia Therapeutics, Inc.
(Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that
, Chief Executive Officer, will present virtually at the H.C. Wainwright 24
Annual Global Investment Conference. The hybrid conference will take place September 12–14, 2022.
The presentation will be available on-demand beginning
September 12, 2022
through the Investors section of Akebia’s website at
for approximately 90 days.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in
. For more information, please visit our website at
, which does not form a part of this release.
Akebia Therapeutics Contact
View original content to download multimedia:
SOURCE Akebia Therapeutics
Featured image: Megapixl © Visivasnc